DataMeds AI, Inc.(MEDS)— Stock Profile, AI Score & Financials

Consumer Staples · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

DataMeds AI, Inc. (MEDS) stock profile, AI quality score, and SEC EDGAR financial data, a Consumer Staples sector company. MEDS is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $23.3m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), DataMeds AI, Inc. reports quarterly revenue of $1.8M, net income of $-18.4M. Top institutional holders of MEDS by reported 13-F value include JANE STREET GROUP, GEODE CAPITAL MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. MEDS trades on the Nasdaq exchange and files with the SEC under CIK 2030763. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MEDS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for DataMeds AI, Inc. directly from SEC EDGAR.